Agonistic Effects of MIF (MSH-Release Inhibiting Factor) in Levodopa-Treated Parkinsonian Patients

  • E. Schneider
  • P.-A. Fischer
  • P. Jacobi
  • W. Reeh
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für Neurologie book series (VDGNEUROLOGIE, volume 1)


The use of Pro-Leu-Gly-NH2 (PLG) synthezised by NAIR et al (9) and considered as MSH-release inhibiting factor (MIF-I) in the treatment of parkinsonism is based on clinical and experimental findings. It could be shown that the application of MSH leads to an aggravation of the parkinsonian symptomatology. In animal studies it was shown that PLG (MIF-I) is able to potentiate the effects of levodopa and to antagonize the effects of reserpine and oxotremorine (for review see 8, 3). The positive effects of PLG (MIF-I) on the parkinsonian symptomatology, first shown by KASTIN and BARBEAU (2) using doses of 20-40 mg , soon were confirmed by CHASE et al (4) and FISCHER et al (6) who, in addition, could demonstrate mood elevating properties of PLG (MIF-I). This latter finding was confirmed also with larger doses of PLG in parkinsonian patients (7) and patients with endo-geneous depression (5). In the present study an analysis of the levodopa potentiating effect on motor performances, mood and drive was carried out.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barbeau A (1975) Potentiation of levodopa effect by intravenous L-propyl-L-leucyl-glycine amide in man. Lancet II: 683–684CrossRefGoogle Scholar
  2. 2.
    Barbeau A, Kastin AJ (1976) Polypeptide therapy in Parkinson’s disease — a new approach. In: Birkmayer W, Hornykiewicz O (eds) Advances in Parkinsonism. Editiones Roche, Basle, p 483–487Google Scholar
  3. 3.
    Barbeau A, Roy M, Gonce M, Labrecque R (1979) Newer therapeutic approaches in Parkinson’s disease. In Poirier LJ, Sourkes TL, Bédard PJ (eds), Adv Neurol Vol 24, The extrapyramidal system and its disorders. Raven Press, New York, p 433–450Google Scholar
  4. 4.
    Chase TN, Woods AC, Lipton MA, Morris CE (1974) Hypothalamic releasing factors and Parkinson’s disease. Arch Neurol 31: 55–56PubMedCrossRefGoogle Scholar
  5. 5.
    Ehrensing RH, Kastin AJ (1978) Dose-related biphasic effect of propyl-leucyl-glycinamide (MIF-I) in depression. Am J Psychiat 135: 562–566PubMedGoogle Scholar
  6. 6.
    Fischer PA, Schneider E, Jacobi P, Maxion H (1974) Effect of melanocyte-stimulating hormone-release inhibiting factor (MIF) in Parkinson’s syndrome. Eur Neurol 12: 360–368PubMedCrossRefGoogle Scholar
  7. 7.
    Gerstenbrand F, Binder H, Grünberger J, Kozmac C, Pusch St, Reisner Th (1976) Infusion therapy with MIF (melanocyte inhibiting factor) in Parkinson’s disease. In: Birmayer W, Hornykiewicz O, (eds) Advances in Parkinsonism. Editiones Roche, Basle, p 456–461Google Scholar
  8. 8.
    Gonce M, Barbeau A (1978) Essais physiologiques avec le M. I. F.-I. dans la maladie de Parkinson. Rev Neurol (Paris) 134: 141–150Google Scholar
  9. 9.
    Nair RMG, Kastin AJ, Schally AV (1971) Isolation and structure of hypothalamic MSH release-inhibiting hormone. Biochem Biophys Res Commun 43: 1376–1381PubMedCrossRefGoogle Scholar
  10. 10.
    Schneider E, Fischer P-A, Jacobi P, Reeh W (1978) Der Einfluß von MIF (Melanozyten inhibierender Faktor) auf Psychomotorik und Stimmungsverhalten von Parkinsonkranken. Arzneim Forsch (Drug Res) 28: 1296–1297Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1980

Authors and Affiliations

  • E. Schneider
  • P.-A. Fischer
  • P. Jacobi
  • W. Reeh

There are no affiliations available

Personalised recommendations